Zealand, underwhelmed by Sanofi's Soliqua sales, plans to ride solo on future launches

sanofi
After partnering with Sanofi on diabetes drug Soliqua, Zealand pharma plans to launch rare disease drug glepaglutide on its own. (Sanofi)

Zealand Pharma’s Big Pharma marketing partnership for diabetes drug Soliqua has left it wanting. So much so, in fact, that it’s planning to go it alone when it comes to future launches.

Sanofi, which is hawking Soliqua, “has said that this doesn’t live up to their expectations. … They had hoped and believed it would be easier to convince the doctors,” CEO Britt Meelby Jensen told Reuters at the company’s headquarters on the outskirts of Copenhagen.

After a January launch, Sanofi reported $17 million in Soliqua sales for the first nine months of last year. And Zealand is getting just 10% in royalties on that disappointing haul, Jensen said.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

RELATED: It's on: With simultaneous FDA nods, Sanofi and Novo to vie for combo-med market

So from here on out, it’ll be riding solo in the launch department, starting with the rollout of glepaglutide. The drug, which treats the rare disease short bowel syndrome, will head into phase 3 trials this year.

“If we give up control to a pharma company we will be evaluated against their internal portfolio and there is a risk of you getting assigned to a lower priority,” Jensen said.

Of course, navigating a partnerless launch is a lot easier in the rare-disease field than it is in a crowded, Big Pharma-dominated space such as diabetes. Zealand estimates that with a launch in 2021 or 2022, glepaglutide can take “a majority” of the $1 billion U.S. short bowel syndrome market.

RELATED: Sanofi beats Novo to launch with diabetes combo Soliqua, kicking off the market-share grab

And the price to play is much lower, too. “It is much more interesting” to get “the full revenue rather than 10%,” Jensen said. “We can do that within rare diseases where investments for getting it to the market are at a lower level than within diabetes.”

That’s not to say the Danish drugmaker is giving up hope for Soliqua. The drug is facing stiff competition in Novo Nordisk’s Xultophy, despite having beaten that product to market. But “we are in dialogue with Sanofi and there is no doubt that they still see it as a strategic important product,” Jensen said.

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.